Skip to main content

Table 2 Characteristics of subjects used in the study (plasma and serum)

From: RIG-1 receptor expression in the pathology of Alzheimer’s disease

Group

Braak stage

AD (CERAD)

Age at death

Gender

Apoe

PMI (hours)

NCI

0

B = CERAD Probable

92

M

3/5

3.33

NCI

0

No

85

F

3/3

2.50

NCI

1

No

90

F

2/3

4.00

NCI

1

No

100

F

2/3

2.25

NCI

1

No

84

F

3/4

3.00

NCI

1

No

79

F

3/4

1.75

MCI

2

B = CERAD Probable

91

F

3/4

1.75

MCI

2

B = CERAD Probable

93

F

3/4

2.75

MCI

2

B = CERAD Probable

80

F

3/4

2.00

MCI

2

A = CERAD Probable

81

M

3/5

2.83

MCI

2

C = Definite AD

79

M

3/3

1.75

MCI

4

B = CERAD Probable

77

M

3/4

2.75

MCI

3

B = CERAD Probable

92

F

2/3

3.25

AD

6

C = Definite AD

78

M

3/4

3.50

AD

6

C = Definite AD

84

M

3/4

2.75

AD

6

C = Definite AD

83

F

3/3

3.50

AD

6

B = CERAD Probable

85

M

3/3

2.75

AD

6

B = CERAD Probable

80

M

3/3

2.75

AD

6

C = Definite AD

87

M

3/4

3.25

AD

6

C = Definite AD

73

M

3/3

2.00

AD

6

C = Definite AD

80

F

3/3

4.00

AD

6

C = Definite AD

83

F

3/4

2.25

AD

5

C = Definite AD

91

F

3/3

3.00

  1. AD: Alzheimer’s disease, Apoe, apolipoprotein e; CERAD: Consortium to Establish a Registry for AD: MCI: mild cognitive impairment, NCI: no cognitive impairment, PMI: postmortem interval.